<DOC>
	<DOCNO>NCT01982643</DOCNO>
	<brief_summary>The aim 2-stage , 3-site study investigate effectiveness safety combination extended-release depot naltrexone plus extended-release bupropion potential pharmacotherapy methamphetamine ( MA ) use disorder .</brief_summary>
	<brief_title>Accelerated Development Additive Pharmacotherapy Treatment Methamphetamine Use Disorder</brief_title>
	<detailed_description>Stage 1 include 20 individual severe stimulant use disorder ( methamphetamine type ) enrol across three study site . Following maximum 30-day screening period establish eligibility , participant receive monthly injection extended-release depot naltrexone ( XR-NTX ; Vivitrol® ) plus once-daily bupropion extended-release tablet ( BRP ; Wellbutrin XL® ) 8 week . Take-home oral study medication ( BRP ) dispense weekly dose non-clinic day . Participants ask attend clinic twice weekly observe BRP dosing , collection urine sample , assessment , medical management . Following 8-week active medication phase , participant complete follow-up phase , include medication taper post-medication phase follow-up visit Week 9 . If Stage 1 data document success ( see criterion ) least 3 `` responder '' study participant , Stage 2 follow utilize protocol Stage 1 , enroll additional group 29 participant . Using criterion `` responder '' success , combine stage document success least 9 49 study participant , combination medication consider show sufficient potential advance large-scale placebo-controlled trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Be 18 65 year age ; Be able speak English sufficiently understand study procedure provide write informed consent participate study ; Demonstrate understanding study procedure correctly answer question consent competency tool ; Be interested reduce stop methamphetamine use ; Meet DSM5 criterion severe methamphetamine use disorder ; Meet subjective objective methamphetamine use criterion define protocol ; Meet subjective objective measure opioidfree prior enrollment medication induction per study medical clinician 's determination ( include pass naloxone challenge ) ; Agree use study cellphone record videos takehome dose transfer study team . If female childbearing potential , agree use acceptable birth control method participation study ; Have know allergy sensitivity study medication ; Have medical history condition would make study participation difficult unsafe ; Have acute psychiatric disorder condition would make study participation difficult unsafe ; Liver function test result great 5 time upper limit normal exclusionary clinical lab test value ; Recent ongoing treatment medication , judgment study medical clinician , could interact adversely study drug interfere study participation ; Have current pattern alcohol , benzodiazepine , sedativehypnotic use , determine study medical clinician , would preclude safe participation ; Pending action situation might prevent remain area duration study prevent participation study activity Be currently pregnant breastfeeding ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>